NASDAQ:SANA Sana Biotechnology (SANA) Stock Forecast, Price & News $3.77 -0.10 (-2.58%) (As of 10:39 AM ET) Add Compare Share Share Today's Range$3.74▼$3.8650-Day Range$3.77▼$5.9852-Week Range$2.99▼$8.01Volume159,069 shsAverage Volume1.13 million shsMarket Capitalization$742.46 millionP/E RatioN/ADividend YieldN/APrice Target$9.40 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Sana Biotechnology MarketRank™ ForecastAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside142.9% Upside$9.40 Price TargetShort InterestBearish22.94% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.70Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.57) to ($1.51) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.06 out of 5 starsMedical Sector561st out of 969 stocksBiological Products, Except Diagnostic Industry83rd out of 162 stocks 3.3 Analyst's Opinion Consensus RatingSana Biotechnology has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 3 buy ratings, 3 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $9.40, Sana Biotechnology has a forecasted upside of 142.9% from its current price of $3.87.Amount of Analyst CoverageSana Biotechnology has only been the subject of 3 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted22.94% of the float of Sana Biotechnology has been sold short.Short Interest Ratio / Days to CoverSana Biotechnology has a short interest ratio ("days to cover") of 25, which indicates bearish sentiment.Change versus previous monthShort interest in Sana Biotechnology has recently decreased by 3.67%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldSana Biotechnology does not currently pay a dividend.Dividend GrowthSana Biotechnology does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SANA. Previous Next 3.2 News and Social Media Coverage News SentimentSana Biotechnology has a news sentiment score of 0.70. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Sana Biotechnology this week, compared to 2 articles on an average week.Search Interest8 people have searched for SANA on MarketBeat in the last 30 days. MarketBeat Follows1 people have added Sana Biotechnology to their MarketBeat watchlist in the last 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Sana Biotechnology insiders have not sold or bought any company stock.Percentage Held by Insiders34.90% of the stock of Sana Biotechnology is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions68.37% of the stock of Sana Biotechnology is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Sana Biotechnology are expected to grow in the coming year, from ($1.57) to ($1.51) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Sana Biotechnology is -2.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sana Biotechnology is -2.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSana Biotechnology has a P/B Ratio of 1.48. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Sana Biotechnology (NASDAQ:SANA) StockSana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others. Its product candidates include SG299 and SG242 that targets CD19+ cancer cells in patients with non-Hodgkin Lymphoma (NHL), chronic lymphocytic leukemia (CLL), and acute lymphoblastic leukemia (ALL); SG221 and SG239 for the treatment of multiple myeloma; and SG233, a CD22 CAR for the treatment of NHL, CLL, and ALL. It also develops SG418 for sickle cell disease and beta-thalassemia; SC291, a CD19 allogeneic T cell therapy; SC255, a B cell maturation antigen directed allogeneic CAR T for multiple myeloma; SC45, the PSC-derived pancreatic islet cells for type I diabetes mellitus; and SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, Huntington's disease, and other astrocytic diseases. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. The company was incorporated in 2018 and is based in Seattle, Washington.Read More SANA Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SANA Stock News HeadlinesSeptember 28, 2023 | americanbankingnews.comSana Biotechnology, Inc. (NASDAQ:SANA) Receives $9.50 Average PT from BrokeragesSeptember 26, 2023 | americanbankingnews.comSana Biotechnology (NASDAQ:SANA) Receives New Coverage from Analysts at JMP SecuritiesOctober 2, 2023 | Edge On The Street (Ad)Gold Could Be Heading for Record Highs - But How to Play It?According to FX Empire, the gold forecast is now bullish, with support for a $3,000 target in 2024. The big question is how to play it. Some investors are discovering a unique gold investment alternative that sidesteps the major issues with gold mining stocks or physical gold. September 25, 2023 | msn.comJMP Securities Initiates Coverage of Sana Biotechnology (SANA) with Market Outperform RecommendationSeptember 25, 2023 | americanbankingnews.comAnalyzing Sana Biotechnology (NASDAQ:SANA) and VectivBio (NASDAQ:VECT)September 25, 2023 | markets.businessinsider.comPromising Prospects and Diversified Portfolio Bolster Sana Biotechnology’s Investment Appeal: A Buy Rating AnalysisSeptember 24, 2023 | americanbankingnews.comSana Biotechnology (NASDAQ:SANA) Shares Down 3.3% September 14, 2023 | seekingalpha.comSana Biotechnology falls after pipeline updatesOctober 2, 2023 | Wall Street Fundamentals (Ad)How is This "Hidden Gem" Thriving in a Turbulent Market?While Wall Street flounders and giants like Amazon & Microsoft lay off thousands... One overlooked company has been quietly achieving over 400% growth. How? By buying, building, and scaling a portfolio of promising brands in high-margin, recession-resistant verticals.September 11, 2023 | finance.yahoo.comFlagship Pioneering Announces Appointment of Amanda Kay as Chief Business Development OfficerSeptember 8, 2023 | msn.comThis Cathie Wood Stock Is Down 40% in 2023. Here's Why She's Still Buying It.September 5, 2023 | markets.businessinsider.comSana Biotechnology (SANA) Initiated with a Buy at CitiAugust 30, 2023 | finance.yahoo.comSana Biotechnology to Present at September 2023 Investor ConferencesAugust 14, 2023 | msn.comTD Cowen Initiates Coverage of Sana Biotechnology (SANA) with Market Perform RecommendationAugust 14, 2023 | finance.yahoo.comFlagship Pioneering Appoints Jason Gardner as CEO-Partner and CEO of Ampersand BiomedicinesAugust 3, 2023 | msn.comSana Biotechnology Non-GAAP EPS of -$0.45 misses by $0.02August 3, 2023 | finance.yahoo.comSana Biotechnology Reports Second Quarter 2023 Financial Results and Business UpdatesAugust 3, 2023 | msn.comBusiness briefs: Biotech breaks ground on new Bothell facilityAugust 1, 2023 | seekingalpha.comSana Biotechnology: Uncertainties Shadowing The PotentialJuly 31, 2023 | bizjournals.comSana breaks ground on manufacturing facility in BothellJuly 24, 2023 | finance.yahoo.comSpecific Biologics Strengthens Scientific Advisory Board with Appointment of Tirtha Chakraborty, Ph.D. and Mike Nicholson, Ph.D.July 18, 2023 | finance.yahoo.comUPDATE 1-Pfizer, Flagship Pioneering to invest $100 mln in drug discoveryJuly 18, 2023 | msn.comPfizer, Flagship Pioneering to invest $100 million in drug discoveryJuly 18, 2023 | reuters.comPfizer, Flagship Pioneering to invest $100 mln for drug discoveryJuly 13, 2023 | finance.yahoo.comFlagship Pioneering Announces Appointment of Rupert Vessey as Chief ScientistJuly 11, 2023 | finance.yahoo.comAPIE Therapeutics Appoints Ashwin Datt Chief Executive OfficerJuly 9, 2023 | seekingalpha.comSana Biotechnology: Hypoimmune Platform Might Stealth CellsSee More Headlines Receive SANA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sana Biotechnology and its competitors with MarketBeat's FREE daily newsletter. Email Address SANA Company Calendar Last Earnings8/03/2023Today10/01/2023Next Earnings (Estimated)11/01/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SANA CUSIPN/A CIK1770121 Websana.com Phone206-701-7914FaxN/AEmployees424Year FoundedN/APrice Target and Rating Average Stock Price Forecast$9.40 High Stock Price Forecast$13.00 Low Stock Price Forecast$6.00 Forecasted Upside/Downside+142.9%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.89) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-269,480,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-73.07% Return on Assets-42.55% Debt Debt-to-Equity RatioN/A Current Ratio3.02 Quick Ratio3.02 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.62 per share Price / Book1.48Miscellaneous Outstanding Shares196,940,000Free Float128,209,000Market Cap$762.16 million OptionableNot Optionable Beta0.70 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesDr. Steven D. Harr M.D. (Age 53)Pres, CEO & Director Comp: $1.04MDr. Richard C. Mulligan Ph.D. (Age 68)Exec. Vice Chairman & Head of SanaX Mr. Bernard J. Cassidy J.D. (Age 68)Exec. VP, Gen. Counsel & Corp. Sec. Comp: $491.39kMr. Nathan Hardy M.B.A. (Age 47)Exec. VP & CFO Brittany MccleeryAccounting Mang.Dr. Edward Rebar Ph.D. (Age 55)Sr. VP & CTO Ms. Robin Andrulevich (Age 57)Exec. VP & Chief People Officer Mr. Paul Brunetta M.D.Sr. VP and Head of Clinical & Translational ScienceMr. Christian Hordo M.B.A. (Age 40)Exec. VP & Chief Bus. Officer Dr. Sonja Schrepfer M.D. (Age 48)Ph.D., Sr. VP & Head of Hypoimmune Platform More ExecutivesKey CompetitorsAdaptimmune TherapeuticsNASDAQ:ADAPNovavaxNASDAQ:NVAXADMA BiologicsNASDAQ:ADMAAdaptive BiotechnologiesNASDAQ:ADPTImmunityBioNASDAQ:IBRXView All CompetitorsInsiders & InstitutionsBarclays PLCSold 17,377 shares on 9/21/2023Ownership: 0.101%Virginia Retirement Systems ET ALBought 14,000 shares on 8/22/2023Ownership: 0.007%Wells Fargo & Company MNBought 8,560 shares on 8/15/2023Ownership: 0.047%XTX Topco LtdSold 3,137 shares on 8/15/2023Ownership: 0.005%Royal Bank of CanadaBought 4,157 shares on 8/15/2023Ownership: 0.005%View All Insider TransactionsView All Institutional Transactions SANA Stock - Frequently Asked Questions Should I buy or sell Sana Biotechnology stock right now? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sana Biotechnology in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" SANA shares. View SANA analyst ratings or view top-rated stocks. What is Sana Biotechnology's stock price forecast for 2023? 6 brokers have issued 12 month target prices for Sana Biotechnology's stock. Their SANA share price forecasts range from $6.00 to $13.00. On average, they anticipate the company's share price to reach $9.40 in the next twelve months. This suggests a possible upside of 142.9% from the stock's current price. View analysts price targets for SANA or view top-rated stocks among Wall Street analysts. How have SANA shares performed in 2023? Sana Biotechnology's stock was trading at $3.95 at the start of the year. Since then, SANA shares have decreased by 2.0% and is now trading at $3.87. View the best growth stocks for 2023 here. When is Sana Biotechnology's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 1st 2023. View our SANA earnings forecast. How were Sana Biotechnology's earnings last quarter? Sana Biotechnology, Inc. (NASDAQ:SANA) announced its quarterly earnings data on Thursday, August, 3rd. The company reported ($0.45) EPS for the quarter, missing analysts' consensus estimates of ($0.42) by $0.03. What ETFs hold Sana Biotechnology's stock? ETFs with the largest weight of Sana Biotechnology (NASDAQ:SANA) stock in their portfolio include iShares Genomics Immunology and Healthcare ETF (IDNA).IQ U.S. Small Cap ETF (CSML). When did Sana Biotechnology IPO? (SANA) raised $322 million in an IPO on Thursday, February 4th 2021. The company issued 15,000,000 shares at a price of $20.00-$23.00 per share. Morgan Stanley, Goldman Sachs, J.P. Morgan and BofA Securities acted as the underwriters for the IPO. What is Sana Biotechnology's stock symbol? Sana Biotechnology trades on the NASDAQ under the ticker symbol "SANA." How do I buy shares of Sana Biotechnology? Shares of SANA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Sana Biotechnology's stock price today? One share of SANA stock can currently be purchased for approximately $3.87. How much money does Sana Biotechnology make? Sana Biotechnology (NASDAQ:SANA) has a market capitalization of $762.16 million. The company earns $-269,480,000.00 in net income (profit) each year or ($1.89) on an earnings per share basis. How many employees does Sana Biotechnology have? The company employs 424 workers across the globe. How can I contact Sana Biotechnology? Sana Biotechnology's mailing address is 188 EAST BLAINE STREET SUIT 400, SEATTLE WA, 98102. The official website for the company is sana.com. The company can be reached via phone at 206-701-7914 or via email at investor.relations@sana.com. This page (NASDAQ:SANA) was last updated on 10/2/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sana Biotechnology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.